Unknown

Dataset Information

0

Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.


ABSTRACT: Mycobacterium bovis bacillus Calmette-Guérin (BCG), which elicits a degree of protective immunity against tuberculosis, is the most widely used vaccine in the world. Due to its persistence and immunogenicity, BCG has been proposed as a vector for vaccines against other infections, including HIV-1. BCG has a very good safety record, although it can cause disseminated disease in immunocompromised individuals. Here, we constructed a recombinant BCG vector expressing HIV-1 clade A-derived immunogen HIVA using the recently described safer and more immunogenic BCG strain AERAS-401 as the parental mycobacterium. Using routine ex vivo T-cell assays, BCG.HIVA(401) as a stand-alone vaccine induced undetectable and weak CD8 T-cell responses in BALB/c mice and rhesus macaques, respectively. However, when BCG.HIVA(401) was used as a priming component in heterologous vaccination regimens together with recombinant modified vaccinia virus Ankara-vectored MVA.HIVA and ovine atadenovirus-vectored OAdV.HIVA vaccines, robust HIV-1-specific T-cell responses were elicited. These high-frequency T-cell responses were broadly directed and capable of proliferation in response to recall antigen. Furthermore, multiple antigen-specific T-cell clonotypes were efficiently recruited into the memory pool. These desirable features are thought to be associated with good control of HIV-1 infection. In addition, strong and persistent T-cell responses specific for the BCG-derived purified protein derivative (PPD) antigen were induced. This work is the first demonstration of immunogenicity for two novel vaccine vectors and the corresponding candidate HIV-1 vaccines BCG.HIVA(401) and OAdV.HIVA in nonhuman primates. These results strongly support their further exploration.

SUBMITTER: Rosario M 

PROVIDER: S-EPMC2876636 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.

Rosario Maximillian M   Hopkins Richard R   Fulkerson John J   Borthwick Nicola N   Quigley Máire F MF   Joseph Joan J   Douek Daniel C DC   Greenaway Hui Yee HY   Venturi Vanessa V   Gostick Emma E   Price David A DA   Both Gerald W GW   Sadoff Jerald C JC   Hanke Tomás T  

Journal of virology 20100407 12


Mycobacterium bovis bacillus Calmette-Guérin (BCG), which elicits a degree of protective immunity against tuberculosis, is the most widely used vaccine in the world. Due to its persistence and immunogenicity, BCG has been proposed as a vector for vaccines against other infections, including HIV-1. BCG has a very good safety record, although it can cause disseminated disease in immunocompromised individuals. Here, we constructed a recombinant BCG vector expressing HIV-1 clade A-derived immunogen  ...[more]

Similar Datasets

| S-EPMC2897629 | biostudies-literature
| S-EPMC3497691 | biostudies-literature
| S-EPMC5542451 | biostudies-literature
2023-06-19 | GSE218271 | GEO
| S-EPMC9491075 | biostudies-literature
| S-EPMC2681965 | biostudies-literature
| PRJNA902836 | ENA
| S-EPMC10409804 | biostudies-literature
| S-EPMC9990026 | biostudies-literature
| S-EPMC10394165 | biostudies-literature